Ognjenka Brkic Vukotic, MD
Internal Medicine · Roswell, GANPI 1023067147
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,296 of the $5,896 with a category attached, or 89.8%. 36 manufacturers reported payments, led by AbbVie at 30.0% of the total. Among internal medicine clinicians in GA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 262 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$2K
- Lilly USA, LLC$672
- GSK$660
- Novo Nordisk$508
- AstraZeneca$396
- Johnson & Johnson$224
- plus $2K from 30 others
Across 100 payments — averaging $4278.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ironwood Pharmaceuticals, Inc$299K
- AbbVie$103K
- Phathom Pharmaceuticals, Inc.$16K
- Novo Nordisk AS$11K
- Janssen Research & Development, LLC$50
What the payments were for
- Speaking & faculty fees$59910%
- Food & beverage$5,29690%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 98 | $1,767 |
| Lilly USA, LLC | 34 | $672 |
| GSK | 4 | $660 |
| Novo Nordisk | 24 | $508 |
| AstraZeneca | 15 | $396 |
| Johnson & Johnson(2 entities) | 2 | $224 |
| Kowa Pharmaceuticals America, Inc. | 12 | $157 |
| Teva Pharmaceuticals USA, Inc. | 8 | $148 |
| Astellas Pharma US Inc | 6 | $145 |
| Pfizer | 7 | $129 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $106 |
| Biohaven Pharmaceutical Holding Company Ltd. | 5 | $103 |
| Biofire Diagnostics, LLC | 1 | $81 |
| Lundbeck LLC | 3 | $66 |
| Currax Pharmaceuticals LLC | 5 | $65 |
| Exact Sciences | 4 | $63 |
| Abbott | 3 | $61 |
| Merck | 3 | $59 |
| Otsuka America Pharmaceutical, Inc. | 2 | $50 |
| Sanofi Pasteur Inc. | 2 | $45 |
| Axsome Therapeutics, Inc. | 2 | $44 |
| Shire North American Group Inc | 2 | $39 |
| Nevro Corp. | 1 | $32 |
| Eisai Inc. | 2 | $29 |
| Inspire Medical Systems, Inc. | 1 | $26 |
| Paratek Pharmaceuticals, Inc. | 1 | $25 |
| Medtronic | 1 | $24 |
| Medicure Pharma Inc. | 1 | $24 |
| Supernus Pharmaceuticals, Inc. | 1 | $21 |
| Sanofi-aventis U.S. LLC | 1 | $21 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| Neos Therapeutics, LP | 1 | $19 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $19 |
| Nalpropion Pharmaceuticals LLC | 1 | $17 |
| Amgen | 1 | $15 |
| Linus Health, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,896 in reported general payments places this provider in the 90th percentile of 3,311 internal medicine providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MounjaroTirzepatide | 24 | $38,506 |
| OzempicSemaglutide | 33 | $36,859 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $36,508 |
| EliquisApixaban | 21 | $26,093 |
| LinzessLinaclotide | 13 | $11,935 |
| Breo ElliptaFluticasone/Vilanterol | 18 | $9,452 |
| BelsomraSuvorexant | 13 | $5,759 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 19 | $4,144 |
| SynthroidLevothyroxine Sodium | 39 | $4,001 |
| Levothyroxine Sodium | 302 | $3,364 |
| Rosuvastatin Calcium | 202 | $1,776 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $1,618 |
| Estradiol (Twice Weekly)Estradiol | 17 | $1,477 |
| Metoprolol Succinate | 110 | $1,410 |
| Bupropion XlBupropion Hcl | 63 | $1,309 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix | $660 | $50,10481 claims |
| Lilly USA, LLCMounjaro | $672 | $38,50624 claims |
| Novo NordiskOzempic | $508 | $36,85933 claims |
| PfizerEliquis | $129 | $26,09321 claims |
| AbbVieLinzess, Synthroid | $1,767 | $15,93752 claims |
| MerckBelsomra | $59 | $5,75913 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,311 internal medicine providers in Georgia.
Other internal medicine in Roswell
- Kaya CaldwellRoswell$22K
- Michael GibsonSmyrna$2.2M
- Eduard FatakhovAlpharetta$376K
- Tracey HenryAtlanta$305K
- Sharon TuckettVilla Rica$265K
- Ebon BourneMarietta$242K
- Jennifer WoehlerSavannah$207K
- Julian HutchinsGreensboro$201K
- Brian PearlmanDalton$199K
- Scott ParryAtlanta$162K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.